STICHTING INTERNATIONAL AIDS VACCINE INITIATIVE THE NETHERLANDS

Their core work

IAVI Netherlands is the European arm of the International AIDS Vaccine Initiative, a global non-profit scientific organization dedicated to accelerating the development of HIV vaccines. Their core work involves contributing immunological and virological expertise to large multi-institutional HIV vaccine research consortia, particularly in the design and evaluation of vaccine candidates across the prophylactic and therapeutic spectrum. They bring a combination of scientific platform capabilities — immunology assays, virology tools — and operational expertise in innovative clinical trial design to projects that span from early discovery through human evaluation. As a globally connected NGO, they act as a bridge between the EU research ecosystem and international HIV vaccine development networks.

What they specialise in

How they've shifted over time

The organization's H2020 involvement began with EAVI2020 (from 2015), a broad European AIDS vaccine initiative where no specific sub-topic keywords were recorded — suggesting a general participation role. By the time EHVA launched in 2016, the profile sharpened considerably: keywords point to defined platform capabilities in immunology and virology, a specific focus on trial methodology, and data integration as a cross-cutting competency. The direction is one of increasing specificity rather than broadening scope — moving from general HIV vaccine participation toward defined technical contributions in platform science and trial design.

This organization is deepening its contribution toward platform-based vaccine evaluation and clinical methodology rather than diversifying — making them a reliable specialist partner for future HIV or broad infectious disease vaccine trials that require immunological infrastructure and non-standard trial design.

How they like to work

IAVI Netherlands exclusively joins as a consortium participant — it has never led an H2020 project as coordinator, reflecting a deliberate model of embedding its expertise within larger research alliances rather than building its own administrative infrastructure. Despite this, the network it operates within is substantial: 61 unique partners across 19 countries, which is unusually broad for just two projects and indicates both EAVI2020 and EHVA are very large-scale consortia. This suggests they are a valued specialist node in pre-existing HIV research networks rather than a project-building organization.

With 61 consortium partners spanning 19 countries across only 2 projects, IAVI Netherlands is embedded in among the largest and most internationally connected consortia in European HIV research. Their network is almost certainly a reflection of IAVI's global footprint rather than independently built European ties.

What sets them apart

IAVI Netherlands brings the weight of a globally recognized HIV vaccine organization into the European research funding landscape — this is not an academic group trying to build vaccine expertise, but a purpose-built NGO whose entire mission is HIV vaccine development. For a consortium targeting HIV vaccine trials or immunological evaluation, they offer access to an international network of clinical sites, validated assay platforms, and decades of institutional knowledge that no university department can replicate. Their Amsterdam base also makes them an accessible, legally straightforward partner within the EU regulatory environment.

Highlights from their portfolio

• EHVA
  The European HIV Vaccine Alliance was a major EU platform project for HIV vaccine discovery and evaluation — IAVI's participation here, with documented keywords around platform science and trial design, represents the clearest evidence of their technical contribution.
• EAVI2020
  A long-running (2015–2022) flagship European AIDS vaccine initiative that placed IAVI alongside the continent's leading HIV research institutions, establishing their EU consortium presence.